Kumar P, Koach J, Nekritz E, Mukherjee S, Braun B, Dubois S
EJNMMI Res. 2024; 14(1):54.
PMID: 38869684
PMC: 11176152.
DOI: 10.1186/s13550-024-01112-7.
Schafer J, Gassenmaier S, Warmann S, Urla C, Frauenfeld L, Flaadt T
J Clin Med. 2023; 12(23).
PMID: 38068349
PMC: 10707530.
DOI: 10.3390/jcm12237297.
Zhang W, Li X, Zeng J, Wen X, Zhang C, Zhang Y
Mater Today Bio. 2023; 23:100828.
PMID: 37822451
PMC: 10562674.
DOI: 10.1016/j.mtbio.2023.100828.
Kalapurakal J, Wolden S, Haas-Kogan D, Laack N, Hua C, Paulino A
Pediatr Blood Cancer. 2023; 70 Suppl 6:e30593.
PMID: 37486145
PMC: 10588230.
DOI: 10.1002/pbc.30593.
Qiu B, Matthay K
Nat Rev Clin Oncol. 2022; 19(8):515-533.
PMID: 35614230
DOI: 10.1038/s41571-022-00643-z.
The application and value of radiotherapy at the primary site in patients with high-risk neuroblastoma.
Wei Z, Li J, Jin Y, Liu Y, Wang P, Cao Y
Br J Radiol. 2022; 95(1134):20211086.
PMID: 35312349
PMC: 10996409.
DOI: 10.1259/bjr.20211086.
Neuroblastoma.
Chung C, Boterberg T, Lucas J, Panoff J, Valteau-Couanet D, Hero B
Pediatr Blood Cancer. 2021; 68 Suppl 2:e28473.
PMID: 33818884
PMC: 8785544.
DOI: 10.1002/pbc.28473.
Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry.
Jazmati D, Butzer S, Hero B, Ahmad Khalil D, Merta J, Baumer C
Front Oncol. 2021; 10:617506.
PMID: 33552991
PMC: 7855697.
DOI: 10.3389/fonc.2020.617506.
Diagnostic Use of Post-therapy I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma.
Wakabayashi H, Kayano D, Inaki A, Araki R, Kuroda R, Akatani N
Diagnostics (Basel). 2020; 10(9).
PMID: 32887257
PMC: 7555271.
DOI: 10.3390/diagnostics10090663.
Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study.
Liu K, Naranjo A, Zhang F, Dubois S, Braunstein S, Voss S
J Clin Oncol. 2020; 38(24):2741-2752.
PMID: 32530765
PMC: 7430214.
DOI: 10.1200/JCO.19.03316.
Patterns of recurrence after radiation therapy for high-risk neuroblastoma.
Jo J, Ahn S, Koh M, Kim J, Lee S, Song S
Radiat Oncol J. 2019; 37(3):224-231.
PMID: 31591871
PMC: 6790795.
DOI: 10.3857/roj.2019.00353.
Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models.
Makvandi M, Lee H, Puentes L, Reilly S, Rathi K, Weng C
Mol Cancer Ther. 2019; 18(7):1195-1204.
PMID: 31072830
PMC: 6606392.
DOI: 10.1158/1535-7163.MCT-18-0837.
Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study.
Braunstein S, London W, Kreissman S, Villablanca J, Davidoff A, DeSantes K
Pediatr Blood Cancer. 2019; 66(7):e27736.
PMID: 30968542
PMC: 7281832.
DOI: 10.1002/pbc.27736.
Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial.
Casey D, Kushner B, Cheung N, Modak S, Basu E, Roberts S
Int J Radiat Oncol Biol Phys. 2019; 104(2):409-414.
PMID: 30763661
PMC: 6499671.
DOI: 10.1016/j.ijrobp.2019.02.004.
Implications of Image-Defined Risk Factors and Primary-Site Response on Local Control and Radiation Treatment Delivery in the Management of High-Risk Neuroblastoma: Is There a Role for De-escalation of Adjuvant Primary-Site Radiation Therapy?.
Lucas Jr J, McCarville M, Cooper D, Doubrovin M, Wakefield D, Santiago T
Int J Radiat Oncol Biol Phys. 2018; 103(4):869-877.
PMID: 30496881
PMC: 8810202.
DOI: 10.1016/j.ijrobp.2018.11.041.
The Children's Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer.
Breneman J, Donaldson S, Constine L, Merchant T, Marcus K, Paulino A
Int J Radiat Oncol Biol Phys. 2018; 101(4):860-874.
PMID: 29976498
PMC: 6548440.
DOI: 10.1016/j.ijrobp.2018.03.002.
Dose-escalation is needed for gross disease in high-risk neuroblastoma.
Casey D, Kushner B, Cheung N, Modak S, LaQuaglia M, Wolden S
Pediatr Blood Cancer. 2018; 65(7):e27009.
PMID: 29469198
PMC: 6625659.
DOI: 10.1002/pbc.27009.
Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?.
Casey D, Pitter K, Kushner B, Cheung N, Modak S, LaQuaglia M
Int J Radiat Oncol Biol Phys. 2018; 100(5):1204-1209.
PMID: 29439882
PMC: 5934297.
DOI: 10.1016/j.ijrobp.2018.01.008.
Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.
Peinemann F, van Dalen E, Enk H, Berthold F
Cochrane Database Syst Rev. 2017; 8:CD010685.
PMID: 28840597
PMC: 6483698.
DOI: 10.1002/14651858.CD010685.pub3.
A single center clinical analysis of children with high-risk neuroblastoma.
Tian X, Cao Y, Wang J, Yan J, Tian Y, Li Z
Oncotarget. 2017; 8(18):30357-30368.
PMID: 28423674
PMC: 5444748.
DOI: 10.18632/oncotarget.15996.